[1]张利娟,张宏涛,王泽阳,等.术中实时计划对腹膜后转移癌125I粒子治疗的剂量学优势 [J].介入放射学杂志,2017,(11):1011-1014.
 ZHANG Lijuan,ZHANG Hongtao,WANG Zeyang,et al.、The advantages of intraoperative TPS real- time planning in treating retroperitoneal metastatic carcinoma with 125I seed brachytherapy [J].journal interventional radiology,2017,(11):1011-1014.
点击复制

术中实时计划对腹膜后转移癌125I粒子治疗的剂量学优势 

()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2017年11期
页码:
1011-1014
栏目:
非血管介入
出版日期:
2017-11-25

文章信息/Info

Title:
、The advantages of intraoperative TPS real- time planning in treating retroperitoneal metastatic carcinoma with 125I seed brachytherapy
作者:
张利娟 张宏涛 王泽阳 赵金鑫 于慧敏 王 娟
Author(s):
ZHANG Lijuan ZHANG Hongtao WANG Zeyang ZHAO Jinxin YU Huimin WANG Juan
Section I, Department of Oncology, Hebei Provincial People’s Hospital, Shijiazhuang, Hebei Province 050000, China
关键词:
【关键词】 腹膜后淋巴结 术中实时计划 125I放射性粒子
文献标志码:
A
摘要:
【摘要】 目的 探讨治疗计划系统(TPS)术中实时计划对CT引导下125I放射性粒子治疗腹膜后淋巴结的必要性及可行性。方法 回顾性分析2013年1月至2015年12月行CT引导下125I放射性粒子治疗的20例腹膜后淋巴结转移癌患者的相关资料,其中10例行TPS术中实时计划指导(A组),10例未行TPS术中实时计划指导(B组),两组患者均行术前计划及术后质量验证。比较A、B两组手术前后90%靶体积的最小吸收剂量(D90)误差百分比、90%处方剂量覆盖的体积占靶体积的百分比(V90)误差百分比、100%处方剂量覆盖的体积占靶体积的百分比(V100)误差百分比、150%处方剂量覆盖的体积占靶体积的百分比(V150)误差百分比的差异。结果 A组手术前后的D90、V90、V100、V150的误差百分比分别为(-1.30±6.80) Gy、(-0.60±2.10)%、(-0.47±2.70)%、(89.60±282.00)%;B组手术前后的D90、V90、V100、V150的误差百分比分别为(-9.33±46.00) Gy、(11.50±13.70)%、(-13.40±15.90)%、(10.37±2.00)%。两组各参数相比较,其中D90、V90、V100误差百分比差异有统计学意义(P<0.05)。两组V150的误差百分比无统计学差异(P=0.247)。结论 术中实时计划指导可显著提高粒子植入前后靶区剂量的一致性,使剂量分布更加合理,对腹膜后淋巴结转移癌125I放射性粒子治疗的规范化具有重要价值。

参考文献/References:

[1] 吴同胜, 韩 潞, 谭卫林, 等. 125I组织间插植放射治疗腹腔内恶性肿瘤的探讨[J]. 中国癌症杂志, 2009, 19: 65- 67.
[2] Huang MW, Liu SM, Zheng L, et al. A digital model individual template and CT- guided 125I seed implants for malignant tumors of the head and neck[J]. J Radiat Res, 2012, 53: 973- 977.
[3] Lin L, Wang J, Jiang Y, et al. Interstitial 125I seed implantation for cervical lymph node recurrence after multimodal treatment of thoracic esophageal squamous cell carcinoma[J]. Technol Cancer Res Treat, 2015, 14: 201- 207.
[4] Gao F, Li C, Gu Y, et al. CT- guided 125I brachytherapy for mediastinal metastatic lymph nodes recurrence from esophageal carcinoma: effectiveness and safety in 16 patients[J]. Eur J Radiol, 2013, 82: e70- e75.
[5] Wu LL, Luo JJ, Yan ZP, et al. Comparative study of portal vein stent and TACE combined therapy with or without endovascular implantation of iodine- 125 seeds strand for treating patients with hepatocellular carcinoma and main portal vein tumor thrombus[J]. Zhonghua Gan Zang Bing Za Zhi, 2012, 20: 915- 919.
[6] Xu KC, Niu LZ, Hu YZ, et al. Cryosurgery with combination of 125iodine seed implantation for the treatment of locally advanced pancreatic cancer[J]. J Dig Dis, 2008, 9: 32- 40.
[7] Wang JJ, Yuan HS, Li JN, et al. Interstitial permanent implantation of 125I seeds as salvage therapy for re- recurrent rectal carcinoma[J]. Int J Colorectal Dis, 2009, 24: 391- 399.
[8] Yoshida K, Ohashi T, Yorozu A, et al. Comparison of preplanning and intraoperative planning for I- 125 prostate brachytherapy[J].Jpn J Clin Oncol, 2013, 43: 383- 389.
[9] Nag S, Bice W, DeWyngaert K, et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis[J]. Int J Radiat Oncol Biol Phys, 2000, 46: 221- 230.
[10] 席 芊, 王培军, 尚鸣异, 等. CT引导下传入淋巴结内无水乙醇腹腔神经丛阻滞木治疗顽固性癌性腹痛[J]. 介入放射学杂志, 2010, 19: 386- 388.
[11] Mendenhall WM, Zlotecki RA, Hochwald SN, et al. Retropertoneal soft tissue sarcoma[J]. Cancer, 2005, 104: 669- 675.
[12] 李荣富, 李 欣, 吴珊珊, 等. 伽马刀放疗腹膜后淋巴结转移癌对肠道菌群的影响[J]. 东南大学学报?医学版, 2012, 31: 72- 78.
[13] Wang JJ, Yuan HS, Li JN, et al. CT- guided radioactive seed implantation for recurrent rectal carcinoma after multiple therapy[J]. Med Oncol, 2010, 27: 421- 429.
[14] Jiang YL, Meng N, Wang JJ, et al. Percutaneous computed tomography / ultrasonography- guided permanent iodine- 125 implan- tation as salvage therapy for recurrent squamous cell cancers of head and neck[J]. Cancer Biol Ther, 2010, 9: 959- 966.
[15] Gao F, Li C, Gu Y, et al. CT- guided 125I brachytherapy for mediastinal metastatic lymph nodes recurrence from esophageal carcinoma: effectiveness and safety in 16 patients[J]. Eur J Radiol, 2013, 82: e70- e75.
[16] Zhu L, Jiang Y, Wang J, et al. An investigation of 125I seed permanent implantation for recurrent carcinoma in the head and neck after surgery and external beam radiotherapy[J]. World J Surg Oncol, 2013, 11: 60.
[17] Lin L, Wang J, Jiang Y, et al. Interstitial 125I seed implantation for cervical lymph node recurrence after multimodal treatment of thoracic esophageal squamous cell carcinoma[J]. Technol Cancer Res Treat, 2015, 14: 201- 207.
[18] Wang H, Wang J, Jiang Y, et al. The investigation of 125I seed implantation as a salvage modality for unresectable pancreatic carcinoma[J]. J Exp Clin Cancer Res, 2013, 32: 106.
[19] Wang Z, Lu J, Gong J, et al. CT- guided radioactive 125I seed implantation therapy of symptomatic retroperitoneal lymph node metastases[J]. Cardiovasc Intervent Radiol, 2014, 37: 125- 131.
[20] Cao Q, Wang H, Meng N, et al. CT- guidance interstitial 125 Iodine seed brachytherapy as a salvage therapy for recurrent spinal primary tumors[J]. Radiat Oncol, 2014, 9: 301.
[21] Blasko JC, Wallner K, Grimm PD, et al. Prostate specific antigen based disease control following ultrasound guided 125 iodine implantation for stage T1/T2 prostatic carcinoma[J]. J Urol, 1995, 154: 1096- 1099.
[22] Stock RG, Stone NN, Wesson MF, et al. A modified technique allowing interactive ultrasound- guided three- dimensional trans- perineal prostate implantation[J]. Int J Radiat Oncol Biol Phys, 1995, 32: 219- 225.
[23] DeMarco JJ, Smathers JB, Burnison CM, et al. CT- based dosimetry calculations for 125I prostate implants[J]. Int J Radiat Oncol Biol Phys, 1999, 45: 1347- 1353.
[24] Zhang L, Mu W, Hu CF, et al. Treatment of portal vein tumor thrombus using 125I odine seed implantation brachytherapy[J].World J Gastroenterol, 2010, 16: 4876- 4879.
[25] 霍 彬, 侯朝华, 叶剑飞, 等. CT引导术中实时计划对胸部肿瘤125I粒子植入治疗的价值[J]. 中华放射肿瘤学杂志, 2013, 22: 400- 403.
[26] Stock RG, Stone NN, Tabert A, et al. A dose- response study for I- 125 prostate implants[J]. Int J Radiat Oncol Biol Phys, 1998, 41: 101- 108.
[27] Ohashi T, Yorozu A, Toya K, et al. Rectal morbidity following I- 125 prostate brachytherapy in relation to dosimetry[J]. Jpn J Clin Oncol, 2007, 37: 121- 126.

备注/Memo

备注/Memo:
(收稿日期:2016-10-27)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2017-11-16